DB:20D

Stock Analysis Report

Executive Summary

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States.


Snowflake Analysis

Adequate balance sheet and fair value.

Share Price & News

How has Cidara Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 20D's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.2%

20D

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-4.3%

20D

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 20D underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 20D exceeded the German Market which returned -17.7% over the past year.


Shareholder returns

20DIndustryMarket
7 Day16.2%11.2%7.3%
30 Day-14.0%-5.3%-17.9%
90 Day-20.1%-21.9%-25.8%
1 Year-4.3%-4.3%-4.9%-5.1%-15.1%-17.7%
3 Year-68.3%-68.3%17.7%16.5%-18.7%-25.6%
5 Yearn/a-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Cidara Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cidara Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 20D (€2.14) is trading below our estimate of fair value (€29.2)

Significantly Below Fair Value: 20D is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 20D is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 20D is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 20D's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 20D is good value based on its PB Ratio (2.2x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Cidara Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

27.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 20D is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 20D is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 20D is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 20D's revenue (47.9% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: 20D's revenue (47.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 20D's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cidara Therapeutics performed over the past 5 years?

-18.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 20D is currently unprofitable.

Growing Profit Margin: 20D is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 20D is unprofitable, and losses have increased over the past 5 years at a rate of -18.4% per year.

Accelerating Growth: Unable to compare 20D's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 20D is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 20D has a negative Return on Equity (-108.61%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cidara Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 20D's short term assets ($65.8M) exceed its short term liabilities ($30.2M).

Long Term Liabilities: 20D's short term assets ($65.8M) exceed its long term liabilities ($942.0K).


Debt to Equity History and Analysis

Debt Level: 20D's debt to equity ratio (26.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 20D's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 20D has a low level of unsold assets or inventory.

Debt Coverage by Assets: 20D's debt is covered by short term assets (assets are 6.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 20D has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 20D has less than a year of cash runway if free cash flow continues to reduce at historical rates of -22.3% each year


Next Steps

Dividend

What is Cidara Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 20D's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 20D's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 20D's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 20D's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 20D's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Jeff Stein (64yo)

6.17s

Tenure

US$1,363,737

Compensation

Dr. Jeffrey L. Stein, also known as Jeff, Ph.D., has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein was Principal Financial Of ...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD1.36M) is above average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Stein
President6.17yrsUS$1.36m1.4% $1.2m
Paul Daruwala
COO & Chief Commercial Officer2.17yrsUS$662.42k0.11% $96.5k
Taylor Sandison
Chief Medical Officer3.5yrsUS$678.49k0.16% $139.4k
Kevin Forrest
Founder and Chief Strategy Officer3.67yrsUS$613.24kno data
James Levine
Chief Financial Officer1.25yrsno data0.15% $134.1k
Brady Johnson
Principal Accounting Officer1.58yrsno data0.0092% $8.1k
Jessica Oien
General Counsel & Secretary1.5yrsno data0.0024% $2.1k
Kenneth Bartizal
Chief Development Officer5.67yrsUS$335.42kno data
James Balkovec
Senior Vice President of Research5yrsno datano data
Neil Abdollahian
Chief Business Officer3.67yrsUS$945.58k0.10% $91.5k

3.6yrs

Average Tenure

48yo

Average Age

Experienced Management: 20D's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Stein
President6.17yrsUS$1.36m1.4% $1.2m
Daniel Burgess
Independent Chairman of the Board0.75yrUS$99.32k0.0074% $6.5k
Timothy Franson
Independent Director5yrsUS$91.35k0.0099% $8.7k
Theodore Schroeder
Independent Director5.92yrsUS$98.07kno data
David Gollaher
Independent Director1.5yrsUS$98.89kno data
Chrysa Mineo
Independent Director2yrsUS$179.08kno data

3.5yrs

Average Tenure

64yo

Average Age

Experienced Board: 20D's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 20D insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.7%.


Top Shareholders

Company Information

Cidara Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cidara Therapeutics, Inc.
  • Ticker: 20D
  • Exchange: DB
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$96.827m
  • Listing Market Cap: US$87.764m
  • Shares outstanding: 40.51m
  • Website: https://www.cidara.com

Number of Employees


Location

  • Cidara Therapeutics, Inc.
  • 6310 Nancy Ridge Drive
  • Suite 101
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CDTXNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDApr 2015
20DDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2015
20DBRSE (Berne Stock Exchange)YesCommon SharesCHCHFApr 2015

Biography

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. Its lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. The company, through its Cloudbreak platform, focuses on the treatment of infectious diseases that include viral and bacterial infections. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 23:17
End of Day Share Price2020/03/30 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.